Eli Lilly and Company (NYSE:LLY) Trading 0.1% Higher

Shares of Eli Lilly and Company (NYSE:LLY - Get Free Report) traded up 0.1% on Friday . The stock traded as high as $774.87 and last traded at $771.61. 461,636 shares were traded during mid-day trading, a decline of 85% from the average session volume of 3,000,582 shares. The stock had previously closed at $771.12.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on LLY shares. Bank of America raised their price target on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a "buy" rating in a research note on Friday, March 1st. JPMorgan Chase & Co. boosted their price target on Eli Lilly and Company from $850.00 to $900.00 and gave the company an "overweight" rating in a report on Wednesday, May 1st. TheStreet upgraded Eli Lilly and Company from a "c+" rating to a "b" rating in a report on Friday, March 8th. BMO Capital Markets upped their target price on Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an "outperform" rating in a research note on Wednesday, May 1st. Finally, The Goldman Sachs Group raised their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a "neutral" rating in a research note on Thursday, April 11th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and an average price target of $769.53.

Eli Lilly and Company Stock Down 0.1 %

The stock has a market capitalization of $731.82 billion, a P/E ratio of 113.64, a P/E/G ratio of 1.56 and a beta of 0.37. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. The stock's 50 day simple moving average is $760.50 and its 200 day simple moving average is $682.89.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, topping analysts' consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. During the same period last year, the firm earned $1.62 earnings per share. The company's revenue for the quarter was up 26.0% compared to the same quarter last year. As a group, research analysts predict that Eli Lilly and Company will post 13.82 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Shareholders of record on Thursday, May 16th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.68%. Eli Lilly and Company's payout ratio is currently 76.58%.

Institutional Investors Weigh In On Eli Lilly and Company

Several large investors have recently added to or reduced their stakes in LLY. Wahed Invest LLC raised its holdings in shares of Eli Lilly and Company by 15.5% during the first quarter. Wahed Invest LLC now owns 16,660 shares of the company's stock valued at $12,961,000 after buying an additional 2,231 shares during the last quarter. Citizens Financial Group Inc. RI raised its stake in Eli Lilly and Company by 0.9% during the 1st quarter. Citizens Financial Group Inc. RI now owns 39,599 shares of the company's stock valued at $30,806,000 after acquiring an additional 340 shares in the last quarter. CCM Investment Advisers LLC raised its stake in Eli Lilly and Company by 1,263.7% during the 1st quarter. CCM Investment Advisers LLC now owns 14,605 shares of the company's stock valued at $11,362,000 after acquiring an additional 13,534 shares in the last quarter. National Wealth Management Group LLC grew its stake in shares of Eli Lilly and Company by 163.6% in the first quarter. National Wealth Management Group LLC now owns 1,189 shares of the company's stock worth $925,000 after purchasing an additional 738 shares in the last quarter. Finally, New Covenant Trust Company N.A. bought a new position in shares of Eli Lilly and Company in the first quarter worth $2,550,000. 82.53% of the stock is owned by institutional investors and hedge funds.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.